Fabry Australia is thrilled to read the announcement on listing Galafold® (migalastat)


Fabry Australia is thrilled to read the announcement on listing Galafold® (migalastat) to treat patients diagnosed with Fabry Disease on the Life Saving Drugs Program on Thursday 1st of November. This listing announcement means the Australian Fabry patient community with amenable mutations now have treatment choice when speaking to their doctors about how to best manage the debilitating effects of their disease. To read the full story Press Here


0 views

+61 (0)412 462 732

Fabry Australia Inc.  |  ABN 70 053 079 595  | Registered Number A0029817E
Terms & Conditions